• Rocío Reinoso Arija, Rosario Ruiz-Serrano de la Espada, Mª Dolores Núñez Ollero, Laura Carrasco Hernandez, GallegoEsther QuintanaEQUnidad Médico-Quirúrgica de Enfermedades Respiratorias. Instituto de Biomedicina de Sevilla (IBiS). Hospital Universitario Virgen del Rocío/Universidad de Sevilla, Seville, Spain.Centro de Investigación Biomédica en Red de Enfermed, and Jose Luis López-Campos.
• Unidad Médico-Quirúrgica de Enfermedades Respiratorias. Instituto de Biomedicina de Sevilla (IBiS). Hospital Universitario Virgen del Rocío/Universidad de Sevilla, Seville, Spain.
• Ann Fam Med. 2024 Sep 1; 22 (5): 417420417-420.

AbstractThe aim of this work is to test whether the use of a transparent capsule affects the residual capsule weight after inhalation as a surrogate of the inhaled delivered dose for patients with non-reversible chronic airway disease. Researchers conducted an observational cross-sectional study with patients using a single-dose dry powder inhaler. The weight of the capsule was measured with a precision microbalance before and after inhalation. Ninety-one patients were included, of whom 63 (69.2%) used a transparent capsule. Inhalation with a transparent capsule achieved a weight decrease of 30.1% vs 8.6% for devices with an opaque capsule (P <0.001). These data reinforce the need to provide patients with mechanisms that verify the correct inhalation technique.© 2024 Annals of Family Medicine, Inc.

15 keywords...

hide…